The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 11, 2009, Pages 651-658

  Linnebjerg, Helle ^a   Kothare, P ^a   Park, S ^a   Mace, K ^a   Mitchell, M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Drug interaction; Exenatide; Lisinopril; Pharmacodynamics; Pharmacokinetics

Indexed keywords

EXENDIN 4; LISINOPRIL; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; NAUSEA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING;

EID: 70449379980     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47651     Document Type: Article

References (29)

1. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, Dawes M, Ebbs D, Farmer A, Robinson J. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 1994; 12: 1053-1060.
2. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy sub jects. J Clin Pharmacol. 2005; 45: 570-577.
3. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care. 2004; 27: 2628-2635.
4. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association, American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007; 30: 162-172.
5. Clark LA, Denby L, Pregibon D, Harshfield GA, Pickering TG, Blank S, Laragh JH. A quantitative analysis of the effects of activity and time of day on the diurnal variations of blood pressure. J Chronic Dis. 1987; 40: 671-681.
6. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care. 2005; 28: 1092-1100.
7. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992; 19: 403-418.
8. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B, Lead-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomized, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373: 473-481.
9. Gentilcore D, Bryant B, Wishart JM, Morris HA, Horowitz M, Jones KL. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med. 2005; 118: 1289.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med. 2008a; 359: 1577-1589.
11. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in Type 2 diabetes. N Engl J Med. 2008b; 359: 1565-1576.
12. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner CK, Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabetic Medicine. 2002; 19: 177-194.
13. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-1091.
14. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-286.
15. Kohara K, Uemura K, Takata Y, Okura T, Kitami Y, Hiwada K. Postprandial hypotension: evaluation by ambulatory blood pressure monitoring. Am J Hypertens. 1998; 11: 1358-1363.
16. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with Type 2 diabetes mellitus. Am J Health Syst Pharm. 2005; 62: 173-181.
17. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, Lim M, Mace KF, Wise SD. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005; 45: 1032-1037.
18. Kothare PA, Seger M, Mace K, Fineman M, Taylor K, Reddy S, Trautmann M, Mitchell M, Linnebjerg H. Effects of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women. The AAPS Journal. 2007a; S2: 9.
19. Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, Han J, Fineman M, Mitchell M. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007b; 45: 114-120.
20. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in Type 2 diabetes. Regulatory Peptides. 2008; 151: 123-129.
21. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007; 50: 259-267.
22. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. N Engl J Med. 1991; 324: 130-131.
23. Russo A, Stevens JE, Wilson T, Wells F, Tonkin A, Horowitz M, Jones KL. Guar attenuates fall in postprandial blood pressure and slows gastric emptying of oral glucose in Type 2 diabetes. Dig Dis Sciences. 2003; 48: 1221-1229.
24. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006; 46: 1179-1187.
25. Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin-based therapies for Type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 2008; 4: 101-109.
26. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in Type 2 diabetic patients. Diabetes Care. 1999; 22: 1137-1143.
27. Working Party of the International Diabetes Federation (European Region). Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med. 2003; 20: 972-987.
28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000; 284: 3043-3045.
29. Zdravkovic M, Ekblom M, Brondsted L, Vouis J, Lennernas H, Malm-Erjefalt M. The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects. Diabetologia. 2008; 51: 355.